YILING PHARMACEUTICAL(SZ:002603) Xin Lang Cai Jing·2025-09-15 11:11Core Viewpoint - The company held an online earnings briefing on September 15, where it addressed investor inquiries regarding product promotion, sales performance, and future strategies [1]. Group 1: Product Focus - The Ba Zi Bu Shen capsules received attention for their effectiveness, but consumers face challenges in understanding the product's target audience, usage methods, and side effects, prompting a call for increased promotional efforts [2]. - The company stated that Ba Zi Bu Shen capsules are developed based on the theory of Qi and are classified as OTC Class A drugs, with multiple studies confirming their positive effects on age-related diseases [2]. Group 2: Financial Performance - For the first half of 2025, the company reported a revenue of 4.04 billion yuan, a year-on-year decrease of 12.26%, while net profit attributable to shareholders rose by 26.03% to 669 million yuan [3]. - The net profit excluding non-recurring items increased by 27.08% to 641 million yuan, and the net cash flow from operating activities surged by 214.97% to 832 million yuan [3]. - The company emphasized that operational quality is improving and plans to leverage its "Seventh Five-Year" strategy to enhance management, R&D, and marketing for stable growth [3]. Group 3: Future Strategies - The company has established a subsidiary, Shanghai Yiling Pharmaceutical, to advance the development of biopharmaceutical products and enhance its competitive edge in this area [3]. - The company is monitoring policies related to the collection of traditional Chinese medicine in Hubei and plans to increase R&D investment to cultivate new products and expand market share [3]. - The year 2025 is identified as a critical year for the "Seventh Five-Year" plan, focusing on technological innovation, results transformation, and industry development to achieve annual operational and profit targets [3].